PIRS NASDAQ
Pieris Pharmaceuticals, Inc.
1W: -16.7%
1M: -15.5%
3M: -18.1%
1Y: +21.4%
3Y: -94.6%
5Y: -95.2%
$13.60
Last traded 2024-12-13 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
By Geography
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
$0
+0.0% ▲
Operating Income
$0
+0.0% ▲
Net Income
-$42M
-139.3% ▼
EPS (Diluted)
$-3.71
+52.6% ▲
EBITDA
$0
+0.0% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $31M | $26M | $43M | $0 | $0 |
| YoY Growth | +7.1% | -17.6% | +65.3% | -100.0% | +0.0% |
| Cost of Revenue | $2M | $3M | $42M | $0 | $0 |
| Gross Profit | $29M | $23M | $1M | $0 | $0 |
| Gross Margin | 92.5% | 89.3% | 2.4% | — | — |
| R&D Expenses | $67M | $53M | $42M | $8M | $23M |
| SG&A Expenses | $17M | $16M | $17M | $6M | $16M |
| Operating Expenses | $80M | $61M | $73M | $14M | $39M |
| Operating Income | -$52M | -$43M | -$30M | $0 | $0 |
| Operating Margin | -165.0% | -167.8% | -69.5% | — | — |
| Interest Expense | $0 | $0 | $0 | -$4M | -$6M |
| Income Before Tax | -$46M | -$33M | -$25M | -$17M | -$42M |
| Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$43M | -$31M | -$25M | -$17M | -$42M |
| Net Margin | -138.0% | -120.7% | -57.3% | — | — |
| EPS (Diluted) | $-53.75 | $-33.71 | $-21.80 | $-7.83 | $-3.71 |
| EBITDA | -$46M | -$33M | -$23M | $0 | $0 |
| Shares Outstanding | 806838 | 927150 | 1M | 2M | 11M |